Physician profile
Stuart D Miller
NPI 1659315844
$583,160.63
in general payments reported to CMS, 2019-2025
21 companies · $99K in 2025
The $99K reported for 2025 was more than what 95% of Foot and Ankle Surgery providers received nationally (typical 2025 total: $1,200).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79K · 2020: $53K · 2021: $91K · 2022: $81K · 2023: $89K · 2024: $91K · 2025: $99K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $218K · Consulting Fee: $45K · Food and Beverage: $8,767 · Travel and Lodging: $7,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $218,196.29 |
| Consulting Fee | $44,616.45 |
| Food and Beverage | $8,767.26 |
| Travel and Lodging | $7,435.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $220,629.35 | 2019-2025 | Phoenix |
| Depuy Synthes Sales INC. | $176,787.25 | 2022-2025 | Motoband, Na |
| Crossroads Extremity Systems, LLC | $87,714.26 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $34,133.29 | 2024-2025 | |
| Ortho Solutions INC | $16,946.79 | 2021 | |
| Ossio INC | $15,339.42 | 2019-2024 | |
| Biocomposites INC | $5,710.47 | 2020-2024 | Stimulan |
| Depuy Synthes Products, INC. | $5,054.96 | 2024 | |
| Medical Device Business Services, INC. | $4,660.48 | 2019-2024 | |
| Arthrex, INC. | $4,038.12 | 2022-2025 | Distal Extremities Implants Soft Tissue Anchors |
| Synthes USA Products LLC | $3,682.03 | 2019 | |
| Exactech, INC. | $3,600.09 | 2021-2025 | |
| Supreme Orthopedic Systems, LLC | $1,846.49 | 2022-2023 | |
| Paragon 28, INC. | $1,235.32 | 2019-2024 | Portfolio, Joust Beaming, Grappler |
| Musculoskeletal Transplant Foundation INC. | $653.96 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $566.71 | 2021-2023 | Zynrelef |
| Native Surgical, LLC | $515.34 | 2025 | |
| Smith+Nephew, INC. | $31.20 | 2019 | |
| Stryker Corporation | $15.10 | 2024 | Infinity Adaptis |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$306,120.76 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.